Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Non-Current Liabilities fell 2.70% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 2.70%. This contributed to the annual value of $2.8 billion for FY2024, which is 3.87% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Total Non-Current Liabilities stood at $2.8 billion, which was down 1.27% from $2.8 billion recorded in Q2 2025.
  • Ptc Therapeutics' Total Non-Current Liabilities' 5-year high stood at $2.9 billion during Q2 2024, with a 5-year trough of $1.6 billion in Q1 2021.
  • Over the past 3 years, Ptc Therapeutics' median Total Non-Current Liabilities value was $2.8 billion (recorded in 2024), while the average stood at $2.5 billion.
  • As far as peak fluctuations go, Ptc Therapeutics' Total Non-Current Liabilities soared by 139.35% in 2021, and later declined by 2.70% in 2025.
  • Over the past 5 years, Ptc Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $1.7 billion in 2021, then increased by 11.32% to $1.9 billion in 2022, then skyrocketed by 41.79% to $2.7 billion in 2023, then increased by 3.87% to $2.8 billion in 2024, then fell by 2.70% to $2.8 billion in 2025.
  • Its Total Non-Current Liabilities was $2.8 billion in Q3 2025, compared to $2.8 billion in Q2 2025 and $2.8 billion in Q1 2025.